In a major leap toward self-reliance in defense technology, India is set to develop its very own fifth-generation fighter jet—the Advanced Medium Combat Aircraft (AMCA) . In a historic move, Defence Minister Rajnath Singh has approved an innovative execution model for the indigenous stealth fighter programme. This model brings together Hindustan Aeronautics Limited (HAL) and private industry players in a competitive framework, marking a significant shift in how India approaches military aviation manufacturing. This bold initiative comes at a critical time, as China has already fielded two fifth-generation fighters , and reports indicate it will supply 40 J-35 stealth jets to Pakistan . Against this backdrop, fast-tracking the AMCA has become an urgent national security imperative. AMCA: India’s Indigenous Stealth Fighter Dream The AMCA project , spearheaded by the Aeronautical Development Agency (ADA) under the Defence Research and Development Organisation (DRDO) , received its l...
Hemophilia A, a hereditary bleeding disorder caused by the deficiency of clotting Factor VIII, has long been a challenge for the medical community. With patients often requiring lifelong injections of clotting factors, treatment remains both costly and inconvenient. However, Indian scientists have recently achieved a groundbreaking milestone by successfully testing a gene therapy technique aimed at curing severe Hemophilia A. This innovative approach promises a one-time treatment that could revolutionize the lives of thousands of patients worldwide. Understanding Hemophilia A Hemophilia A is a genetic disorder characterized by the deficiency or malfunction of Factor VIII, an essential protein involved in blood clotting. Patients with severe hemophilia have less than 1% of the normal clotting factor levels, making them prone to spontaneous and potentially life-threatening bleeding episodes. Global and National Impact India has the second-largest hemophilia patient pool globally, with e...